These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12792983)

  • 1. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
    Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
    In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
    Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
    Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
    Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
    Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: contribution to Fas-mediated apoptosis.
    Pyrovolaki K; Mavroudi I; Sidiropoulos P; Eliopoulos AG; Boumpas DT; Papadaki HA
    Arthritis Rheum; 2009 Feb; 60(2):543-52. PubMed ID: 19180486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
    Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
    Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells.
    Akel SM; Atoum MF; Saleh SA; Awadallah SM
    Saudi Med J; 2005 Oct; 26(10):1523-8. PubMed ID: 16228049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
    Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
    Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
    Koukourakis GV; Baksevanis CN; Zambatis H; Gritzapis A; Maltezos E; Simopoulos C; Koukourakis MI
    Int J Radiat Biol; 2009 Jan; 85(1):96-104. PubMed ID: 19205988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.
    Hirano T; Hiratsuka N; Iwahori T; Oka K; Wakasugi K
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():315-28. PubMed ID: 15686130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome.
    Micheva I; Thanopoulou E; Michalopoulou S; Kakagianni T; Kouraklis-Symeonidis A; Symeonidis A; Zoumbos N
    Br J Haematol; 2004 Sep; 126(6):806-14. PubMed ID: 15352984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.
    Lorand-Metze I; Ribeiro E; Lima CS; Batista LS; Metze K
    Leuk Res; 2007 Feb; 31(2):147-55. PubMed ID: 16750852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
    Bowen DT; Denzlinger C; Brugger W; Culligan D; Gelly K; Adlakha S; Groves M; Hepburn M; Kanz L
    Br J Haematol; 1998 Dec; 103(3):785-7. PubMed ID: 9858231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved hematopoiesis using amifostine in secondary myelodysplasia.
    Auletta JJ; Shurin S
    J Pediatr Hematol Oncol; 1999; 21(6):531-4. PubMed ID: 10598667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression.
    Ribeiro E; Lima CS; Metze K; Lorand-Metze I
    Leuk Lymphoma; 2004 Feb; 45(2):309-13. PubMed ID: 15101716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.